Dr. Maxwell V. Meng

Dr. Maxwell V. Meng, MD, is a nationally recognized urologic oncologist specializing in the surgical management of genitourinary cancers. He serves as Professor of Urology at the University of California, San Francisco (UCSF), where he is Chief of the Urologic Oncology Division and Director of the Urologic Oncology Fellowship Program. Dr. Meng earned his medical degree from the Johns Hopkins University School of Medicine and completed both his general surgery and urology residency at UCSF. He went on to receive additional fellowship training in minimally invasive surgery and urologic oncology, also at UCSF, where he has remained a key leader in clinical care, research, and education.

Dr. Meng is known for his expertise in performing advanced robotic and laparoscopic procedures to treat cancers of the kidney, bladder, prostate, and testis. He is particularly focused on functional outcomes and quality-of-life preservation in surgical cancer treatment. His research spans a wide range of topics, including molecular profiling of bladder cancer, immunotherapeutic approaches, and biomarker discovery. He has published extensively in leading urologic and oncologic journals and has contributed numerous book chapters to the academic literature. As a clinical trial investigator, he plays a pivotal role in evaluating new therapies and refining surgical techniques for complex urologic malignancies.

Beyond his clinical and research contributions, Dr. Meng is a dedicated educator and mentor, training residents and fellows through UCSF’s highly respected urologic programs. He serves on editorial boards and contributes to national guideline development in urologic oncology. Widely respected by patients and peers alike, he is consistently recognized for his excellence in surgical care and compassionate approach. Through his leadership in minimally invasive surgery, translational research, and surgical education, Dr. Meng continues to advance the field of urologic oncology and improve outcomes for patients with genitourinary cancers.